Stephanie van Hoppe

187 List of publications · Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S , de Waart DR, Tolenaars D, van der Meer JHM, Wildenberg M, Beuers U, Oude Elferink RPJ, Schinkel AH, van de Graaf SFJ. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice, Hepatology, 5 (2017) 1631-1643. 10.1002/hep.29251 · van Hoppe S , Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability, Mol Pharm, 11 (2018) 5124-5134. 10.1021/acs. molpharmaceut.8b00702 · Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S , Beijnen JH, Schinkel AH. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice, Pharmacol Res, (2018) 414-423. 10.1016/j.phrs.2017.11.006 · Van Hoppe S , Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (Breast Cancer Resistance Protein), Pharmacol Res. 2019 Aug;146:104297. · Martínez-Chávez A, van Hoppe S , Rosing H, Lebre CM, Tibben M, Beijnen JH, Schinkel AH. P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability, Mol Pharm. 2019; in press · Rood JJM, Jamalpoor A, van Hoppe S , van Haren MJ, Wasmann RE, Janssen MJ, Schinkel AH, Masereeuw R, Schellens JHM, Beijnen JH, Sparidans RW. Extrahepatic metabolism of the targeted covalent inhibitor ibrutinib through the glutathione cycle. In preparation